Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer
AssigneeGeron Corporation
InventorFederico C. A. Gaeta
Life of this patent
Estimating the term…
Abstract
The invention provides a method of activating a T lymphocyte by contacting the T lymphocyte with a dendritic cell (DC) that presents a telomerase reverse transcriptase (TRT) peptide in the context of a MHC class I or MHC class II molecule. The DC may be pulsed with a TRT polypeptide or may comprise a recombinant polynucleotide encoding a TRT such as hTRT. The invention also provides DCs comprising a recombinant TRT polynucleotide. The methods and compositions of the invention are used in prevention and treatment of cancers and other cell proliferation diseases or conditions.
Claims22
A composition comprising antigen-presenting cells containing a polypeptide that comprises at least 6 consecutive amino acids of telomerase reverse transcriptase (TRT;
- SEQ. ID NO:2), and a pharmaceutical carrier suitable for human administration;
- whereupon administration of the composition to a human subject induces an anti-TRT immunological response.
A method for preparing cytotoxic T cells specific for telomerase reverse transcriptase (TRT), comprising combining T lymphocytes ex vivo with antigen-presenting cells containing a polypeptide that comprises at least 6 consecutive amino acids of telomerase reverse transcriptase (TRT;
- SEQ. ID NO:2), so as to cause T lymphocytes specific for TRT to proliferate.
An isolated cytotoxic T cell specific for telomerase reverse transcriptase (TRT).
Dependencies are inferred from the claim text.